Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 5/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 7/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320408 | 1.00 | PSMB1 (0.47) | PSMB1PSMB5NTSR1TNFHDAC3 | |
| SCHEMBL25321476 | 0.86 | PSMB1 (0.42) | PSMB1PSMB5NTSR1TNFHDAC3 | |
| SCHEMBL25321479 | 0.86 | PSMB1 (0.42) | PSMB1PSMB5NTSR1TNFHDAC3 | |
| SCHEMBL30550799 | 0.86 | PSMB1 (0.42) | PSMB1PSMB5NTSR1TNFHDAC3 | |
| SCHEMBL25897715 | 0.81 | HTR2A (0.49) | PSMB1PSMB5NTSR1TNFHDAC3 | |
| SCHEMBL20786967 | 0.77 | PSMB1 (0.47) | PSMB1PSMB5NTSR1TNFEGLN1 | |
| SCHEMBL20786901 | 0.77 | TNF (0.41) | PSMB1PSMB5TNFHDAC3HDAC1 | |
| SCHEMBL20786928 | 0.77 | HDAC3 (0.47) | PSMB1PSMB5TNFHDAC3HDAC1 | |
| SCHEMBL1725380 | 0.74 | TNF (0.39) | PSMB1PSMB5TNFHDAC3HDAC1 | |
| SCHEMBL20808939 | 0.74 | MAPK1 (0.51) | PSMB1PSMB5TNFEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | PSMB1 1952/4885PSMB5 1412/4885NTSR1 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.